EW
Bearish signalScored 2026-10-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Research, not advice.
À propos
Edwards Lifesciences Corporation
- Nom
- Edwards Lifesciences Corporation
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NYSE
- Capitalisation
- $51.7B
- Employés
- 16,000
- PDG
- Bernard J. Zovighian
- Site web
- https://www.edwards.com
- Marché
- AORTAVRGNGBYISRGLIVNOCPNF
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 619 titres (~54169 USD)
- Insiders
- Lippis Daniel J.
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$4,185,103
Avg sell (VWAP, 90d window) $89.61 vs last close $86.60 (-3.4%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$164,153 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-11
- Liquidity
- Liquid $325,983,613/day · 20d vol
- Last synced
-
2026-10-17 09:40:21
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-08 | Lippis Daniel J. | Sell · S · 10b5-1 | 619 | $85.65 | $53,017 | Form 4 |
| 2026-09-11 | Lippis Daniel J. | Sell · S · 10b5-1 | 619 | $87.51 | $54,169 | Form 4 |
| 2026-08-31 | Dahl Andrew M. | Sell · S | 544 | $91.06 | $49,534 | Form 4 |
| 2026-08-28 | Bruls Annette | Sell · S | 2,644 | $89.98 | $237,907 | Form 4 |
| 2026-08-26 | Chopra Daveen | Sell · S | 30,646 | $90.99 | $2,788,547 | Form 4 |
| 2026-08-26 | Markowitz Wayne | Sell · S | 1,240 | $91.47 | $113,417 | Form 4 |
| 2026-08-11 | Lippis Daniel J. | Sell · S · 10b5-1 | 619 | $92.03 | $56,967 | Form 4 |
| 2026-07-30 | Markowitz Wayne | Sell · S | 146 | $86.03 | $12,588 | Form 4 |
| 2026-07-28 | Markowitz Wayne | Sell · S | 9,628 | $85.06 | $818,958 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-05-01 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-01-13 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-11-19 | Josh S. Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2025-10-07 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-05-12 | Jefferson Shreve | Sale (Full) | $50,001 - $100,000 |
| 2025-04-21 | Bruce Westerman | Sale (Full) | $1,001 - $15,000 |
| 2025-04-08 | Robert P. Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-04-07 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-03-03 | Bruce Westerman | Purchase | $1,001 - $15,000 |
| 2024-10-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-04-11 | Mike Kelly | Sale (Full) | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-12-11 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-12-04 | John R. Curtis | Sale (Full) | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-10-26 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-10-02 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-08-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-08-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-07-28 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-06-21 | John R. Curtis | Purchase | $1,001 - $15,000 |
| 2023-05-25 | Zoe Lofgren | Sale (Full) | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-04-26 | John R. Curtis | Purchase | $1,001 - $15,000 |
| 2023-04-25 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-06 | Daniel Goldman | Purchase | $15,001 - $50,000 |
| 2023-01-25 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2023-01-25 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-11-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-10-27 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-10-27 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-10-27 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-09-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-09-08 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-09-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-23 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-07-19 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-06-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-23 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-05-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-05 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-04-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-02-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-21 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-01-20 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2021-09-16 | Katherine M. Clark | Sale (Full) | $1,001 - $15,000 |
| 2021-09-02 | Zoe Lofgren | Purchase | $1,001 - $15,000 |
| 2021-08-09 | Zoe Lofgren | Purchase | $1,001 - $15,000 |
| 2021-07-27 | Katherine M. Clark | Sale (Full) | $1,001 - $15,000 |
| 2021-02-16 | Peter Meijer | Sale (Full) | $1,001 - $15,000 |
| 2021-01-28 | Peter Meijer | Sale (Partial) | $1,001 - $15,000 |
| 2020-11-05 | Katherine M. Clark | Purchase | $1,001 - $15,000 |
| 2020-03-23 | Zoe Lofgren | Sale (Full) | $1,001 - $15,000 |
| 2019-07-30 | Gilbert Ray Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2019-03-20 | Susie Lee | Sale (Full) | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-10-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
EW presents a structurally sound balance sheet with strong liquidity (score: 90), but deteriorating fundamentals — including margin compression, interest coverage dropping to zero, and elevated P/E multiples —…
The first sentence of the analysis written for EW on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. Weekly bias is flat
- Financial indicators Supports a bullish reading. Current ratio 3.72 · operating margin 27%
Suggested stop 81.32, nearest stored support minus 0.5 ATR(6.1% under the last close). Reward/risk to the next stored resistance is 0.09. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 78.1% | 79.5% | 79.3% | 78.3% | 76.6% | |
| Ebit Margin | 21.0% | 28.8% | 27.7% | 33.3% | 33.0% | |
| Ebitda Margin | 23.6% | 31.7% | 30.6% | 36.4% | 36.1% | |
| Operating Profit Margin | 27.0% | 25.3% | 28.5% | 31.6% | 30.8% | |
| Pretax Profit Margin | 21.0% | 28.5% | 27.4% | 32.8% | 32.5% | |
| Continuous Operations Profit Margin | 17.4% | 25.7% | 24.4% | 28.3% | 28.7% | |
| Net Profit Margin | 17.7% | 76.7% | 28.0% | 28.3% | 28.7% | |
| Bottom Line Profit Margin | 17.7% | 76.7% | 28.0% | 28.3% | 28.7% | |
| Current Ratio | 3.716 | 4.176 | 3.376 | 3.028 | 3.081 | |
| Quick Ratio | 3.095 | 3.454 | 2.620 | 2.172 | 2.377 | |
| Solvency Ratio | 0.366 | 1.447 | 0.585 | 0.679 | 0.625 | |
| Cash Ratio | 1.620 | 2.023 | 0.947 | 0.752 | 0.836 | |
| Price To Earnings Ratio | 46.332 | 10.606 | 33.009 | 30.329 | 53.755 | |
| Price To Earnings Growth Ratio | -0.629 | 0.052 | -5.413 | 14.619 | 0.651 | |
| Forward Price To Earnings Growth Ratio | -0.629 | 0.052 | -5.413 | 14.619 | 0.651 | |
| Price To Earnings Diluted Ratio | 46.585 | 10.621 | 33.152 | 30.578 | 54.433 | |
| Price To Earnings Diluted Growth Ratio | -0.632 | 0.052 | -5.778 | 12.129 | 0.655 | |
| Price To Book Ratio | 4.823 | 4.425 | 6.957 | 7.954 | 13.837 | |
| Price To Sales Ratio | 8.216 | 8.135 | 9.234 | 8.580 | 15.432 | |
| Price To Free Cash Flow Ratio | 37.344 | 152.631 | 73.488 | 48.441 | 57.583 | |
| Price To Operating Cash Flow Ratio | 31.253 | 81.593 | 51.642 | 37.911 | 46.619 | |
| Debt To Assets Ratio | 0.051 | 0.054 | 0.073 | 0.083 | 0.081 | |
| Debt To Equity Ratio | 0.068 | 0.070 | 0.103 | 0.119 | 0.118 | |
| Debt To Capital Ratio | 0.064 | 0.065 | 0.093 | 0.106 | 0.106 | |
| Long Term Debt To Capital Ratio | 0.055 | 0.056 | 0.082 | 0.093 | 0.093 | |
| Financial Leverage Ratio | 1.325 | 1.306 | 1.408 | 1.428 | 1.457 | |
| Working Capital Turnover Ratio | 1.250 | 1.428 | 2.039 | 2.550 | 2.408 | |
| Operating Cash Flow Ratio | 0.880 | 0.360 | 0.749 | 1.192 | 1.678 | |
| Operating Cash Flow Sales Ratio | 0.263 | 0.100 | 0.179 | 0.226 | 0.331 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.837 | 0.535 | 0.703 | 0.783 | 0.810 | |
| Debt Service Coverage Ratio | 49.494 | 79.343 | 78.551 | 65.454 | 68.194 | |
| Interest Coverage Ratio | 0.000 | 69.631 | 81.097 | 64.977 | 64.935 | |
| Short Term Operating Cash Flow Coverage Ratio | 65.110 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 2.261 | 0.775 | 1.308 | 1.762 | 2.509 | |
| Capital Expenditure Coverage Ratio | 6.131 | 2.149 | 3.364 | 4.600 | 5.252 | |
| Dividend Paid And Capex Coverage Ratio | 6.131 | 2.149 | 3.364 | 4.600 | 5.252 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 33.313 | 24.318 | 29.848 | 23.519 | 42.631 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 78.1% | ▼-1.3% | ▼-0.2% |
| Ebit Margin | 21.0% | ▼-7.8% | ▼-7.8% |
| Ebitda Margin | 23.6% | ▼-8.1% | ▼-8.1% |
| Operating Profit Margin | 27.0% | ▲1.6% | ▼-1.7% |
| Pretax Profit Margin | 21.0% | ▼-7.5% | ▼-7.5% |
| Continuous Operations Profit Margin | 17.4% | ▼-8.3% | ▼-7.5% |
| Net Profit Margin | 17.7% | ▼-59.1% | ▼-18.2% |
| Bottom Line Profit Margin | 17.7% | ▼-59.1% | ▼-18.2% |
| Current Ratio | 3.716 | ▼-0.460 | ▲0.240 |
| Quick Ratio | 3.095 | ▼-0.359 | ▲0.351 |
| Solvency Ratio | 0.366 | ▼-1.081 | ▼-0.374 |
| Cash Ratio | 1.620 | ▼-0.403 | ▲0.385 |
| Price To Earnings Ratio | 46.331 | ▲35.725 | ▲11.525 |
| Price To Earnings Growth Ratio | -0.629 | ▼-0.682 | ▼-2.485 |
| Forward Price To Earnings Growth Ratio | -0.629 | ▼-0.682 | ▼-2.485 |
| Price To Earnings Diluted Ratio | 46.585 | ▲35.964 | ▲11.511 |
| Price To Earnings Diluted Growth Ratio | -0.632 | ▼-0.684 | ▼-1.917 |
| Price To Book Ratio | 4.823 | ▲0.397 | ▼-2.776 |
| Price To Sales Ratio | 8.216 | ▲0.082 | ▼-1.703 |
| Price To Free Cash Flow Ratio | 37.344 | ▼-115.287 | ▼-36.553 |
| Price To Operating Cash Flow Ratio | 31.253 | ▼-50.340 | ▼-18.551 |
| Debt To Assets Ratio | 0.051 | ▼-0.002 | ▼-0.017 |
| Debt To Equity Ratio | 0.068 | ▼-0.002 | ▼-0.028 |
| Debt To Capital Ratio | 0.064 | ▼-0.002 | ▼-0.023 |
| Long Term Debt To Capital Ratio | 0.055 | ▼-0.002 | ▼-0.021 |
| Financial Leverage Ratio | 1.325 | ▲0.019 | ▼-0.060 |
| Working Capital Turnover Ratio | 1.250 | ▼-0.177 | ▼-0.685 |
| Operating Cash Flow Ratio | 0.879 | ▲0.519 | ▼-0.092 |
| Operating Cash Flow Sales Ratio | 0.263 | ▲0.163 | ▲0.043 |
| Free Cash Flow Operating Cash Flow Ratio | 0.837 | ▲0.302 | ▲0.104 |
| Debt Service Coverage Ratio | 49.494 | ▼-29.850 | ▼-18.713 |
| Interest Coverage Ratio | 0.000 | ▼-69.631 | ▼-56.128 |
| Short Term Operating Cash Flow Coverage Ratio | 65.110 | ▲65.110 | ▲52.088 |
| Operating Cash Flow Coverage Ratio | 2.261 | ▲1.487 | ▲0.538 |
| Capital Expenditure Coverage Ratio | 6.131 | ▲3.982 | ▲1.832 |
| Dividend Paid And Capex Coverage Ratio | 6.131 | ▲3.982 | ▲1.832 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 33.313 | ▲8.995 | ▲2.587 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $49.85B | $44.25B | $46.26B | $46.18B | $80.75B | |
| Enterprise value | $47.62B | $41.90B | $45.81B | $46.11B | $80.58B | |
| EV / Sales | 7.85x | 7.70x | 9.14x | 8.57x | 15.40x | |
| EV / Op. cash flow | 29.85x | 77.27x | 51.14x | 37.85x | 46.52x | |
| EV / Free cash flow | 35.67x | 144.54x | 72.78x | 48.36x | 57.46x | |
| EV / EBITDA | 33.31x | 24.32x | 29.85x | 23.52x | 42.63x | |
| Net debt / EBITDA | -1.56x | -1.36x | -0.29x | -0.04x | -0.09x | |
| Current ratio | 3.72x | 4.18x | 3.38x | 3.03x | 3.08x | |
| Income quality | 1.49x | 0.13x | 0.64x | 0.80x | 1.15x | |
| Graham number | $27 | $51 | $24 | $23 | $23 | |
| Graham net-net | $4 | $3 | $0 | -$0 | -$1 | |
| Tax burden | 84.3% | 269.7% | 102.2% | 86.1% | 88.3% | |
| Interest burden | 100.0% | 98.7% | 98.7% | 98.5% | 98.6% | |
| Working capital | $4.93B | $4.78B | $2.84B | $2.07B | $2.15B | |
| Invested capital | $9.74B | $9.52B | $6.06B | $5.25B | $5.28B | |
| Return on assets | 7.8% | 32.0% | 15.0% | 18.4% | 17.7% | |
| Operating ROA | 12.2% | 12.3% | 16.2% | 20.3% | 20.5% | |
| Return on tangible assets | 9.9% | 41.3% | 17.9% | 22.2% | 21.4% | |
| Return on equity | 10.4% | 41.8% | 21.1% | 26.2% | 25.8% | |
| Return on invested capital | 11.4% | 10.7% | 15.5% | 20.1% | 19.0% | |
| Return on capital employed | 13.8% | 11.9% | 17.5% | 23.4% | 21.6% | |
| Earnings yield | 2.2% | 9.4% | 3.0% | 3.3% | 1.9% | |
| Free cash flow yield | 2.7% | 0.7% | 1.4% | 2.1% | 1.7% | |
| Capex / Op. cash flow | 16.3% | 46.5% | 29.7% | 21.7% | 19.0% | |
| Capex / Depreciation | 166.2% | 162.6% | 183.8% | 189.7% | 244.7% | |
| Capex / Sales | 4.3% | 4.6% | 5.3% | 4.9% | 6.3% | |
| SG&A / Sales | 34.4% | 32.9% | 31.6% | 29.1% | 28.5% | |
| R&D / Sales | 17.8% | 19.4% | 19.2% | 17.6% | 17.3% | |
| Stock comp / Sales | 2.6% | 3.0% | 2.8% | 2.4% | 2.1% | |
| Intangibles / Total assets | 21.1% | 22.6% | 16.5% | 17.5% | 17.5% | |
| Days sales outstanding | 55d | 49d | 60d | 47d | 46d | |
| Days payables outstanding | 63d | 64d | 66d | 63d | 61d | |
| Operating cycle | 365d | 404d | 378d | 321d | 263d | |
| Cash conversion cycle | 302d | 339d | 313d | 258d | 202d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-05 Edwards Lifesciences to Host Investor Event in Conjunction With TCT IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that it will host an investor event in conjunction with the TCT annual scientific symposium in San Diego on Monday, Nov. 2, from 5:00 to 6:00 PM Pacific Time. The meeting will include a live Q&A session with physicians and members of the Edwards management team. A live webcast of the event will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived versio.
- 2026-10-01 Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease who require pulmonary valve replacement. For many pediatric patients, pulmonary valve replacement is not a one-time event. The AUTUS valve is the first FDA-approved surgical pulmonary valve designed for pediatric anatomy,.
- 2026-09-30 Is EW Overvalued? DCF Says Worth $40 On September 30, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has shown a mixed price performance recently, with a ye
- 2026-09-17 Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead Edwards Lifesciences NYSE: EW outlined a strategy centered on structural heart disease, with Chief Executive Officer Bernard Zovighian highlighting five therapy areas that the company views as its principal growth platforms: transcatheter aortic valve replacement for aortic stenosis, PASCAL, EVOQUE, SAPIEN M3 and surgical therapies.
- 2026-09-16 Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
- 2026-09-16 EW DCF Analysis: Intrinsic Value $53 vs Price $86 On September 16, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has experienced a mixed price performance recently. The
- 2026-09-10 Edwards Lifesciences Comments on TAVR National Coverage Decision IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) released by the Centers for Medicare & Medicaid Services (CMS):“Edwards is pleased that this updated policy represents an important step toward improving and expanding patient access to TAVR while reinforcing the value of a multidisciplinary Heart Team. Aortic stenosis is a serious, pro.
- 2026-09-07 Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders? Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
- 2026-09-02 Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.Bernard Zovighian, chief executive officer, is scheduled to present at 10:00 a.m. ET. Doretta Mistras, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessibl.
- 2026-08-29 128,603 Shares in Edwards Lifesciences Corporation $EW Acquired by Beacon Pointe Advisors LLC Beacon Pointe Advisors LLC bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 128,603 shares of the medical research company''s stock, valued at approximately $11,632,000. A number of